Inovio Pharmaceuticals (NASDAQ:INO) announces preliminary data from a Phase 1 clinical trial evaluating COVID-19 DNA vaccine candidate INO-4800 in 40 healthy adult volunteers aged 18 – 50.
Each participant received 1 mg or 2 mg doses four weeks apart, each administered with the company’s Cellectra 2000 device.
94% (n=34/36) showed overall immunological responses based on data assessing humoral (binding and neutralizing) and T cell immune responses. Three participants were excluded from the immune analyses due to testing positive for COVID-19 antibodies at study entry and one discontinued for reasons unrelated to safety or tolerability.
The full dataset will be submitted for publication.
It has expanded the Phase 1 study to include older participants.
The company says INO-4800, selected to participate in an Operation Warp Speed-connected non-human primate challenge study, is the only nucleic acid-based vaccine that is room temperature-stable and does not need to be frozen during storage or transport.
A Phase 2/3 trial should launch this summer.
Shares down 10% premarket on robust volume in what looks like “sell on the news” behavior considering the stock’s 107% rally since June 22.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.